Fig. 6: PDPK1 is the target of miR-1178-3p.

a Targets of miR-1178-3p were predicted by the online databases TargetScan7.2, miRwalk and miRDB; b, c The qPCR and western blotting analysis were used to detect the expression of PDPK1, CHRNB4 and STON2 in the serum of patients with and without postinfarct cardiac remodeling, respectively. GAPDH served as control. Data are mean ± SD. **P < 0.01, N-CR group vs. Control group; ##P < 0.01, CR group vs. N-CR group. CR, postinfarct cardiac remodeling; N-CR, nonpostinfarct cardiac remodeling. d Luciferase reporter assays to verify the binding of miR-1178-3p to PDPK1 at the 3'UTR; e, f Expression of PDPK1 was detected using qRT–PCR and western blotting in VSMCs treated with miR-1178-3p mimics or inhibitors at the mRNA and protein levels, respectively. Data are mean ± SD. **P < 0.01, miR-1178-3p mimics group vs. NC group; ##P < 0.01, miR-1178-3p inhibitor group vs. NC group.